Emmaus Life Sciences Receives Validation From European Medicines Agency on Marketing Authorization Application for Sickle Cell Disease Treatment Xyndari (oral glutamine)
Emmaus Life Sciences, Inc. (Emmaus) announced today that the company’s Marketing Authorization Application (MAA) for Xyndari has been fully validated and is now under assessment by the European Medicines Agency (EMA) for the treatment of sickle cell disease.
“Sickle cell disease patients in the European Union have not had access to new therapies for almost 20 years,” said Yutaka Niihara, MD, MPH, CEO and chairman of Emmaus. “The submission of this application reflects our continued commitment to provide treatment options for this painful and life-threatening disease to as many patients as possible.”
The MAA is supported by data from the company's phase 3 randomized, double-blind, placebo-controlled, multi-center clinical trial of 230 patients ages 5 to 58 years old with sickle cell disease who had two or more painful crises within 12 months prior to enrollment. Patients who were treated with Xyndari over a 48-week period experienced fewer crisis episodes compared to patients who received a placebo (median 3 vs. median 4), fewer hospitalizations for sickle cell pain (median 2 vs. median 3), and fewer days in the hospital (median 6.5 days vs. median 11 days). Study patients on Xyndari also had fewer occurrences of acute chest syndrome, a life-threatening complication of sickle cell disease (8.6 percent vs. 23.1 percent). A sickle cell crisis was defined as a visit to an emergency room/medical facility for sickle cell disease-related pain treated with a parenterally administered narcotic or ketorolac; the occurrence of chest syndrome, priapism, and splenic sequestration were also considered sickle cell crises. The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremity, back pain and chest pain.
Xyndari for the treatment of sickle cell disease will be reviewed by the EMA under the centralized licensing procedure for all 28 member states of the European Union, Norway and Iceland. Xyndari has also received orphan designation and an approved paediatric investigation plan (PIP) from the EMA.
Outside the United States, this treatment is currently available through an early access program based on a named patient use for sickle cell disease patients that have exhausted other treatment options. This program is administered by myTomorrows and provides physicians in the EU, Turkey, Middle East and South America with the possibility to prescribe oral L-glutamine to eligible patients prior to marketing authorization.
The U.S. Food and Drug Administration (FDA) approved Endari™ (L-glutamine oral powder) for the treatment of sickle cell disease, specifically to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older, on July 7, 2017. Endari is currently available by prescription to patients with sickle cell disease in the U.S.
About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fibrous, causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded. Patients with sickle cell disease suffer from debilitating episodes of sickle cell crises, which occur when the rigid, adhesive and inflexible red blood cells occlude blood vessels. Sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue, referred to as tissue ischemia, and inflammation. These events may lead to a variety of other adverse outcomes such as acute chest syndrome that requires hospitalization. Sickle cell disease is an orphan disease, affecting approximately 100,000 patients in the U.S. and millions worldwide with significant unmet medical needs.
Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain and chest pain.
Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation and hot flash.
The safety and efficacy of Endari in pediatric patients with sickle cell disease younger than five years of age has not been established.
For more information, please see full Prescribing Information of Endari at www.ENDARIrx.com/Repository/Prescribing%20information.pdf
About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The company's research on sickle cell disease was initiated by Yutaka Niihara, M.D., MPH, Chairman and CEO of Emmaus, at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
for Emmaus Life Sciences
Lori Teranishi, 510-290-6160
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Skitude Premium Launches, Offering Personalised 3D Mapping, 3D Tracks, Advanced Statistics, Speed Heat Maps and Apple Watch Compatibility18.12.2018 15:58 | Pressemelding
Skitude, the world’s largest apps community of digitally-connected snow sport lovers, with over a million users, has launched a premium version of its popular profile. Skitude apps are available for Android and Apple devices, and the premium upgrade offers the option to see your day’s skiing/boarding as an interactive 3D map, a speed ‘heat map’ or by statistical analysis of descents, slopes and distances covered. There is also Apple Watch compatibility, so your smartphone battery won’t be dead by lunchtime, as can often be the case with tracking apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005591/en/ (Photo: Skitude) Premium also offers 3D maps and advanced statistics for over 2,500 resorts worldwide, with real time information on slope conditions and whether runs are open. There are ‘points of interest’, webcams and a wealth of other useful information to help you make the most of your time on the slopes. Skit
PSB Names Mike Chuter Chief Executive Officer18.12.2018 14:15 | Pressemelding
PSB, a global research-based consultancy within BCW, announced today that Mike Chuter has joined the firm as Chief Executive Officer, effective immediately. Chuter is based in New York and reports to Donna Imperato, Global CEO of BCW. He is responsible for the global growth and development of the organization across its Corporate, Political, Media and Entertainment practices. “Mike is exceptionally well-suited to lead PSB given his deep experience interpreting data through both analytical and creative lenses and in driving integrated communications programs rooted in analytics,” said Imperato. “Mike is the right person to help PSB advise on holistic creative communications solutions that leverage the firm’s industry-leading expertise in primary research and behavioral, social and other third-party data analysis.” Chuter is a 25-year agency veteran who joins PSB from global social impact organization Thankful, which he co-founded in 2013, a one-half commercial enterprise, one-half socia
The Keio Plaza Hotel Tama Creates New “Hello Kitty” Photographic Spot and Sanrio Characters Themed Rooms －“My Melody” and “Little Twin Stars”18.12.2018 14:05 | Pressemelding
The Keio Plaza Hotel Co., Ltd., one of Japan’s most prestigious hotel companies operating hotels located in the Shinjuku district of Tokyo and other locations, is proud to announce that it is fortifying its collaborative relationship with the Sanrio Co., Ltd. (Headquarters: Shinagawa, Tokyo, President and CEO: Shintaro Tsuji) to expand our facilities and services featuring “Hello Kitty” and other Sanrio characters at our Keio Plaza Hotel Tama facility. We will create a new photographic spot within our hotel lobby where guests can take pictures with “Princess Kitty” in March 2019, and renovate another four rooms to become Sanrio characters themed rooms, two rooms each in the themes of “My Melody” and “Little Twin Stars” (Kiki and Lala), in June 2019 in addition to the four existing “Hello Kitty” themed rooms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005251/en/ In Keio Plaza Hotel Tama, a new photo spot based upon
Chartbeat Announces the Most Engaging Stories of 201818.12.2018 12:00 | Pressemelding
Chartbeat, the leading content intelligence platform for publishers, today announces the Most Engaging Stories of 2018, the articles that were read most this year based on highest Engaged Time. Selected from over 60 million pieces of content published on thousands of media sites around the world, the top stories serve as a snapshot of the year’s major events and highlight the themes that resonated most with readers. 2018 saw familiar political and social themes rise to the top, including Brexit, the Trump administration, the #MeToo movement, and climate change, but it was the deeply investigated and deeply personal stories of human struggle from publications like CNN, The New York Times, New York Magazine, and Rolling Stone that topped the list again this year. “Each year, the Most Engaging Stories list proves the power of storytelling. We learn more about the world, of course, but we also learn more about how to make sense of it and each other,” said John Saroff, CEO of Chartbeat. “Th
European DataWarehouse Launches Enhanced Private Data Environment18.12.2018 11:23 | Pressemelding
European DataWarehouse (ED) today announced it has launched an enhanced version of ED Private, a private data environment to report information including energy efficiency and relevant documentation for a variety of instruments such as credit claims, covered bonds, private cash and synthetic ABS transactions, ABCP, whole loan portfolios and private repo transactions. Built on EDitor, an integrated web application, ED Private offers easy and user-friendly access. The solution facilitates controlled transmission of designated information between the issuer, who is responsible for authorising access, and data users. Furthermore, ED Private provides a technical framework for accessing, uploading and downloading information on demand. The enhanced private data environment for documentation and transactions can be used to facilitate reporting to rating agencies, central banks, competent authorities and dedicated investors. The technical framework for the transmission and dissemination of the
ZT Acquires Both Mobile & IoT Messaging and Interact Business Units From NewNet18.12.2018 10:17 | Pressemelding
ZephyrTel, a division of ESW Capital focused exclusively on global telecommunications operators, is pleased to announce it has acquired the Interact and Mobile Messaging business units of NewNet Communication Technologies with immediate effect. The acquisition will integrate the Mobile Messaging, Invigorate Rating and Charging Platform and the Nimblevox Cloud IVR technology into the ZephyrTel rapidly growing Telecoms Cloud Portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005330/en/ ZephyrTel's CEO, Mike Shinya (Photo: Business Wire) ZephyrTel has built a world-class telecommunication Cloud software company to provide software solutions and services to the global telco industry. The company’s primary objective is to provide carrier-grade Cloud applications and Cloud enablement products. The goal being to deliver industry-leading throughput, robustness, scale and value to its customers at the pace they need. Zep